Therapeutic effect by spherical oral adsorbent(Kremezin®) on vascular endothelial function in type 2 diabetic patients with overt nephropathy.
- Conditions
- Type 2 diabetic patients with overt nephropathy.
- Registration Number
- JPRN-UMIN000005981
- Lead Sponsor
- Kanazawa Medical University Diabetes and Endocrinology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Not provided
Exclusion Criteria Patients that meet any of the following Exclusion Criteria must not be enrolled into the study: 1) Patients with transit disorder in the digestive tract or peptic ulcer and esophageal varix (this product may irritate affected area.) and patients whom physician judges as inappropriate 2) Patients with a predisposition to severe and habitual constipation (this product may exacerbate constipation) and patients whom physician judges as inappropriate 3) Patients with severe ketosis, diabetic coma, or precoma 4) Patients with severe infection, before and after operation, or severe injury 5) Patients with hematuria 6) Patients with a previous history of medication allergy 7) Patients who is currently pregnant, or plan to become pregnant during the study period 8) Patients with active diabetic proliferative retinopathy (except for patients with proliferative retinopathy who conducted retinal photocoagulation therapy and were stable on the retina) 9) Patients whom physician determines as inappropriate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Flow-mediated vasodilation(FMD)
- Secondary Outcome Measures
Name Time Method Changes of estimated GFR by Japanese equation, urinary protein to urinary creatinine ratio, parameters related to vascular endothelial function and atherosclerosis (i.e., ADMA, NOx, vWF), NT-proBNP, uremic toxin (i.e., indoxyl sulfate), and oxidative stress(urinary 8-OHdG).